These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 28273730)

  • 1. Arterial dissections during transcatheter arterial chemoembolization for hepatocellular carcinoma: a 19-year clinical experience at a single medical institution.
    Jung E; Shin JH; Kim JH; Yoon HK; Ko GY; Sung KB
    Acta Radiol; 2017 Jul; 58(7):842-848. PubMed ID: 28273730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study.
    Lee S; Kim KM; Lee SJ; Lee KH; Lee DY; Kim MD; Kim DY; Kim SU; Won JY
    Acta Radiol; 2017 Feb; 58(2):131-139. PubMed ID: 27217418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiographic evaluation of hepatic arterial injury after cisplatin and Gelfoam-based transcatheter arterial chemoembolization for hepatocellular carcinoma in a 205 patient cohort during a 6-year follow-up.
    Suh CH; Shin JH; Yoon HM; Yoon HK; Ko GY; Gwon DI; Kim JH; Sung KB
    Br J Radiol; 2014 Sep; 87(1041):20140054. PubMed ID: 24970695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular complications of hepatic artery after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
    Sueyoshi E; Hayashida T; Sakamoto I; Uetani M
    AJR Am J Roentgenol; 2010 Jul; 195(1):245-51. PubMed ID: 20566824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma.
    Li B; Yu J; Wang L; Li C; Zhou T; Zhai L; Xing L
    Am J Clin Oncol; 2003 Aug; 26(4):e92-9. PubMed ID: 12902905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Incidence and risk factors of acute hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma].
    Jeon SH; Park KS; Kim YH; Shin YS; Kang MK; Jang BK; Chung WJ; Cho KB; Hwang JS
    Korean J Gastroenterol; 2007 Sep; 50(3):176-82. PubMed ID: 17885283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcatheter arterial chemoembolization through collateral arteries for hepatocellular carcinoma after arterial occlusion.
    Shibata T; Kojima N; Tabuchi T; Itoh K; Konishi J
    Radiat Med; 1998; 16(4):251-6. PubMed ID: 9814419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma: predictive value of the monoethylglycinexylidide test.
    Huang YS; Chiang JH; Wu JC; Chang FY; Lee SD
    Am J Gastroenterol; 2002 May; 97(5):1223-7. PubMed ID: 12014732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis of clinical prognosis and the correlation between bile duct injury after transcatheter arterial chemoembolization and the level of hepatic arterial embolization in patients with hepatocellular carcinoma].
    Xu HY; Yu XP; Feng R; Hu HJ; Xiao WW
    Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):355-360. PubMed ID: 28535652
    [No Abstract]   [Full Text] [Related]  

  • 10. The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. A prospective controlled study.
    Lee HS; Kim JS; Choi IJ; Chung JW; Park JH; Kim CY
    Cancer; 1997 Jun; 79(11):2087-94. PubMed ID: 9179054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma.
    Imai N; Ikeda K; Seko Y; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
    Oncology; 2011; 80(3-4):188-94. PubMed ID: 21709428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for the development of pulmonary oil embolism after transcatheter arterial chemoembolization of hepatic tumors.
    Wu GC; Chan ED; Chou YC; Yu CY; Hsieh TY; Hsieh CB; Chian CF; Ke FC; Dai YL; Su WL
    Anticancer Drugs; 2014 Sep; 25(8):976-81. PubMed ID: 24736105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arterial injury during transcatheter arterial chemoembolization for hepatocellular carcinoma: predictors of risk and outcome.
    Onizuka H; Sueyoshi E; Ishimaru H; Sakamoto I; Uetani M
    Abdom Radiol (NY); 2017 Oct; 42(10):2544-2550. PubMed ID: 28493072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization on hepatocellular carcinoma.
    Liu C; Sun L; Xu J; Zhao Y
    World J Surg Oncol; 2016 Apr; 14():100. PubMed ID: 27038790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iatrogenic celiac and hepatic artery dissections during intra-arterial regional tumor therapies: a 16-year retrospective review.
    Alexander ES; Nadolski GJ; Soulen MC; Stavropoulos SW; Hunt SJ; Gade TP; Itkin M; Shamimi-Noori S
    Abdom Radiol (NY); 2019 Oct; 44(10):3480-3485. PubMed ID: 31471705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ruptured hepatocellular carcinoma following chemoembolization: a western experience.
    Battula N; Srinivasan P; Madanur M; Chava SP; Priest O; Rela M; Heaton N
    Hepatobiliary Pancreat Dis Int; 2007 Feb; 6(1):49-51. PubMed ID: 17287166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcatheter arterial chemoembolization vs. chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis.
    Kim JH; Yoon HK; Kim SY; Kim KM; Ko GY; Gwon DI; Sung KB
    Aliment Pharmacol Ther; 2009 Jun; 29(12):1291-8. PubMed ID: 19392861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcatheter arterial chemoembolization combined with radiofrequency ablation delays tumor progression and prolongs overall survival in patients with intermediate (BCLC B) hepatocellular carcinoma.
    Yin X; Zhang L; Wang YH; Zhang BH; Gan YH; Ge NL; Chen Y; Li LX; Ren ZG
    BMC Cancer; 2014 Nov; 14():849. PubMed ID: 25409554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiographic evaluation of hepatic arterial damage after transarterial chemoembolization for hepatocellular carcinoma.
    Maeda N; Osuga K; Mikami K; Higashihara H; Onishi H; Nakaya Y; Tatsumi M; Hori M; Kim T; Tomoda K; Nakamura H
    Radiat Med; 2008 May; 26(4):206-12. PubMed ID: 18509720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcatheter arterial chemoembolization therapy combined with percutaneous ethanol injection for unresectable large hepatocellular carcinoma: an evaluation of the local therapeutic effect and survival rate.
    Dohmen K; Shirahama M; Shigematsu H; Miyamoto Y; Torii Y; Irie K; Ishibashi H
    Hepatogastroenterology; 2001; 48(41):1409-15. PubMed ID: 11677976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.